

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1 and 2 (cancelled)

Claim 3. (currently amended) ~~A purified peptide or its derivative according to claim 1~~ A purified peptide having anti-angiogenic functionality of the structure:

Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);

wherein the peptide sequence corresponds to the fourth peptide of peptides of GeneBank LocusID: 4018 which are separated by cysteine units, wherein at least one of amino acids acid of said peptide or derivative is in a D-form.

4. (currently amended) ~~A pharmaceutical composition comprising at least one of said peptide or peptide derivative of claim 3.~~

Claim 5. (currently amended) ~~A purified peptide or its derivative according to claim 1~~ A purified peptide having anti-angiogenic functionality of the structure:

Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);

wherein the peptide sequence corresponds to the fourth peptide of peptides of GeneBank LocusID: 4018 which are separated by cysteine units, wherein one amino acid is removed, replaced, or added to said peptide or derivative to form a new molecule and wherein either a C-terminal protecting group or an N-terminal protecting group is removed from the peptide.

Claim 6. (currently amended) ~~A pharmaceutical produce~~ A purified pharmaceutical product comprising at least one of said a peptide or peptide derivative of claim 5 having anti-angiogenic functionality of the structure:

Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);

wherein the peptide sequence corresponds to the fourth peptide of peptides of GeneBank LocusID: 4018 which are separated by cysteine units, wherein either a C-terminal protecting group or an N-terminal protecting group is removed from the peptide.

7. (currently amended) A The purified peptide ~~or its derivative~~ according to claim 4 3, wherein either a C-terminal protecting group or an N-terminal protecting group is removed from the peptide ~~or derivative~~.

8. (currently amended)A pharmaceutical product comprising ~~at least one of~~ said peptide ~~or derivative~~ of claim 7.

Claims 9-12. (cancelled)